Results 121 to 130 of about 210,637 (269)
The serum hormone profiles of the patients with and without GnRH antagonist administration.
, 2016 L-rFSH w/ GnRH antagonist, the individuals who received GnRH antagonist in the follicular phase; L-rFSH w/o GnRH antagonist, the individuals who did not receive GnRH antagonist in the follicular phase. (A) Serum LH levels of the two groups; the LH levels
Shih-Chieh Huang (2622685) +6 more
core +1 more source
British Journal of Pharmacology, EarlyView.The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral +3 more
wiley +1 more source
Current Approaches to Support Patients to Withdraw From Image and Performance Enhancing Drugs
Clinical Endocrinology, EarlyView.ABSTRACT Image and performance‐enhancing drugs (IPEDs) include agents such as androgens, growth hormone, and erythropoietin, which are used to enhance appearance and physical performance. Androgens, also known as anabolic‐androgenic steroids (AAS), are the most used IPEDs worldwide.
Elizabeth Hyams +3 more
wiley +1 more source
Reproductive Biology and EndocrinologyBackground Previous studies has yielded contradictory findings regarding the relationship between controlled ovarian hyperstimulation (COH) protocol and euploid blastocyst rate. This study aimed to investigate whether progestin-primed ovarian stimulation
Hu Tan +9 more
doaj +1 more source
Orally active gnRH-antagonist AEZS-115 inhibits growth of human ovarian and breast cancers in vitro.
, 2009 Abstract #3065 Introduction: AEZS-115 is an orally active peptidomimetic antagonist of GnRH, which has been shown to block the pituitary GnRH receptor in nanomolar range.
JB Engel +5 more
core +1 more source
Clinical Endocrinology, EarlyView.ABSTRACT Objective Cardiovascular disease (CVD) risk is elevated in transgender individuals during gender‐affirming hormone therapy (GAHT) with expected different mechanisms between T‐ and E2‐based GAHT. We investigated prospective changes in cardiometabolic proteins relating to complement, inflammation, and transport during GAHT.
Emilie Bukh Madsen +12 more
wiley +1 more source
Equine Veterinary Education, EarlyView.Summary Mittelschmerz is a well‐recognised benign peri‐ovulatory pain syndrome in women and, by physiological analogy, may also occur in mares. In equine practice, peri‐ovulatory ovarian pain has been associated with transient discomfort, colic‐like signs and behavioural changes, although its true clinical relevance remains poorly defined.
G. Marino +4 more
wiley +1 more source
Journal of Clinical Periodontology, EarlyView.ABSTRACT Objectives To identify local and systemic risk factors/indicators for dental biofilm‐induced gingivitis (DB‐GI) and to summarize evidence for their control. Methods A systematic review was undertaken following Preferred Reporting Items for Systematic Review and Meta‐Analyses (PRISMA) guidelines and divided into PECOTS and PICOTS questions ...
M. Gosset +6 more
wiley +1 more source
, 2014 Funnel plot of the effect of GnRH long agonist protocol versus GnRH antagonist protocol on clinical pregnancy rate per embryo transfer in full analysis using Random-effects model.
Lin Li (28817) +5 more
core +1 more source
Menopause and vascular endothelial health: Is it all about the oestrogen?
Experimental Physiology, EarlyView.Abstract Cardiovascular disease (CVD) is a leading cause of mortality in women, and CVD risk is accelerated during the menopause transition. This acceleration has traditionally been attributed to the hallmark decline in oestradiol with menopause. However, the menopause transition is also characterized by changes in other sex hormones that exert effects
Virginia R. Nuckols +4 more
wiley +1 more source